Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00043888 · ClinicalTrials.gov registry record · Phase 3
Study to Explore Safety And Tolerability of Fosamprenavir With or Without Ritonavir in Combination With TRIZIVIR or COMBIVIR
A Phase 3 study of HIV Infections, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 3
- Development phase
- 60
- Enrollment target
- 18
- Study locations
NCT00043888: Completed Phase 3 study of HIV Infections, sponsored by GlaxoSmithKline.
NCT00043888 is a Phase 3 study of HIV Infections that has completed, run by GlaxoSmithKline. The registered enrollment target is 60 participants, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (87% lower). The trial reports 18 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00043888, a Phase 3 study of HIV Infections, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 60 participants
- Enrollment target
- 18
- Study locations
Study Summary
Antiretroviral Therapy (ART) naive subjects will be enrolled in this clinical research study to test the safety and tolerability of fosamprenavir with or without ritonavir in combination TRIZIVIR and COMBIVIR. Subjects will receive 24 weeks of therapy.
Conditions Studied
Interventions
- DRUG ritonavir
- DRUG fosamprenavir
- DRUG COMBIVIR
- DRUG TRIZIVIR
Study Locations (18)
Other
- GSK Clinical Trials Call Center - Lyon
- GSK Clinical Trials Call Center - Paris
- GSK Clinical Trials Call Center - Paris
- GSK Clinical Trials Call Center - London
- GSK Clinical Trials Call Center - Manchester
Florida
- GSK Clinical Trials Call Center - Altamonte Springs
- GSK Clinical Trials Call Center - Fort Lauderdale
- GSK Clinical Trials Call Center - Fort Lauderdale
- GSK Clinical Trials Call Center - Fort Lauderdale
California
- GSK Clinical Trials Call Center - Long Beach
- GSK Clinical Trials Call Center - Newport Beach
- GSK Clinical Trials Call Center - San Diego
Arkansas
- GSK Clinical Trials Call Center - Little Rock
Colorado
- GSK Clinical Trials Call Center - Denver
District of Columbia
- GSK Clinical Trials Call Center - Washington D.C.
Georgia
- GSK Clinical Trials Call Center - Atlanta
North Carolina
- GSK Clinical Trials Call Center - Greenville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2002-01 |
| Est. Completion | 2003-05 |
| Phase | Phase 3 |
What the finished NCT00043888 record still lists
NCT00043888 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (87% lower).
The record links to 1 condition, with HIV Infections appearing as the primary indexed condition, and to 4 interventions - of which ritonavir is the first listed.
NCT00043888 lists 18 locations in 9 states (Other, Florida, California).
Frequently Asked Questions
What is clinical trial NCT00043888 about?
NCT00043888 is a clinical study titled "Study to Explore Safety And Tolerability of Fosamprenavir With or Without Ritonavir in Combination With TRIZIVIR or COMBIVIR". Antiretroviral Therapy (ART) naive subjects will be enrolled in this clinical research study to test the safety and tolerability of fosamprenavir with or without ritonavir in combination TRIZIVIR and COMBIVIR. Subjects will receive 24 weeks of therapy.
What is the current status of trial NCT00043888?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 60 participants. The study started on 2002-01. Estimated completion is 2003-05.
What conditions does trial NCT00043888 study?
This clinical trial studies the following conditions: HIV Infections.
What interventions are being tested in trial NCT00043888?
The interventions under investigation include: ritonavir (DRUG), fosamprenavir (DRUG), COMBIVIR (DRUG), TRIZIVIR (DRUG).
Who is sponsoring clinical trial NCT00043888?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00043888 being conducted?
This trial has 18 study locations across Arkansas, California, Colorado, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00043888's enrollment target sits among peer trials
60 322nd of 542 higher than 205 of 542 other HIV Infections trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other HIV Infections trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate the Effectiveness of Long-acting (LA) Cabotegravir (CAB) + Rilpivirine (RPV) LA When Given to Participants With Detectable HIV-1
RECRUITING · Phase 3
-
Testing a Real-time Electronic Antiretroviral Adherence Monitoring Intervention
RECRUITING · Phase 3
-
SmartSteps: A Context-Aware, PrEP Adherence Intervention for Individuals With Substance Use Disorder
RECRUITING · Phase 3
-
Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current Antiretroviral Regimen in Virologically Suppressed HIV-1-infected Adults
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Evaluate Efficacy, Safety and Tolerability in Antiretroviral Therapy (ART)-Experienced Participants of at Least 50 Years of Age Living With Human Immunodeficiency Virus (HIV) With Virologic Suppression Who Switch to DTG/3TC FDC From BIC/FTC/TAF
ACTIVE NOT RECRUITING · Phase 3
-
The LATITUDE Study: Long-Acting Therapy to Improve Treatment SUccess in Daily LifE
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia